FOLH1 and neoplasm: Ferdinandus, J., et al. similarly found that the results of the LuPSMA phase II trial of 177Lu-PSMA-617 revealed MTV, mean intensity of PSMA tumor uptake, bone scan index (BSI), ALP, and LDH as biomarkers prognostic of overall survival [52].